1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CSPC Pharmaceutical Group Ltd.
  6. News
  7. Summary
    1093   HK1093012172

CSPC PHARMACEUTICAL GROUP LTD.

(1093)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-06-27 am EDT
7.790 HKD   -0.26%
06/22CSPC Pharmaceutical Gets Biologic License Approval from China for Bone Treatment
MT
06/22CSPC Pharmaceutical Group Limited Announce Biologic License Application for Jmt103 Accepted by the NMPA
CI
06/14China Grants Approval, Generic Drug Status to CSPC Pharma's Dopamine Agonist
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CSPC Pharmaceutical Group Limited Announces Change of CEO

05/27/2022 | 06:49am EDT

CSPC Pharmaceutical Group Limited announced that Mr. Cai Dongchen has ceased to act as the Chief Executive Officer of the Company in order to focus his time and effort more on the strategic level of the Company and facilitate the arrangement to separate the roles of Chairman and CEO so as to maintain a high standard of corporate governance. Mr. Cai remains as an executive director and Chairman of the Company. Mr. Zhang Cuilong, an executive director, Vice-Chairman and Rotating CEO of the Company, has been appointed as CEO. Mr. Zhang, aged 53, was appointed as an executive director of the Company in 2018 and was appointed as Vice-Chairman and Rotating CEO on 21 May 2019. He is also a director of certain subsidiaries of the Company. Mr. Zhang holds a bachelor's degree in pharmacology from Hebei Medical College (now known as Hebei Medical University) and has extensive technical, marketing and management experience in the pharmaceutical industry.


© S&P Capital IQ 2022
All news about CSPC PHARMACEUTICAL GROUP LTD.
06/22CSPC Pharmaceutical Gets Biologic License Approval from China for Bone Treatment
MT
06/22CSPC Pharmaceutical Group Limited Announce Biologic License Application for Jmt103 Acce..
CI
06/14China Grants Approval, Generic Drug Status to CSPC Pharma's Dopamine Agonist
MT
06/10Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$11.2 From 11.64, Keeps at..
MT
06/02Hong Kong Hang Seng Down 1% On Wall Street Cues, Central Bank Outlooks
MT
05/31Hong Kong Hang Seng Up 1.2% on Easing China Restrictions, Stimulus Outlook
MT
05/31CSPC Pharmaceutical's Hepatitis B Medication Gets Chinese Government Approval
MT
05/31CSPC PHARMACEUTICAL GROUP LTD. : Ex-dividend day for final dividend
FA
05/27CSPC Pharmaceutical Group Limited Announces Change of CEO
CI
05/27CSPC Pharmaceutical Group Limited Announces Appointment of Wu Guizhen as Independent No..
CI
More news
Analyst Recommendations on CSPC PHARMACEUTICAL GROUP LTD.
More recommendations
Financials
Sales 2022 36 633 M 4 667 M 4 667 M
Net income 2022 7 161 M 912 M 912 M
Net cash 2022 14 397 M 1 834 M 1 834 M
P/E ratio 2022 13,0x
Yield 2022 1,97%
Capitalization 93 060 M 11 856 M 11 856 M
EV / Sales 2022 2,15x
EV / Sales 2023 1,78x
Nbr of Employees 24 746
Free-Float 70,4%
Chart CSPC PHARMACEUTICAL GROUP LTD.
Duration : Period :
CSPC Pharmaceutical Group Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSPC PHARMACEUTICAL GROUP LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 7,81 HKD
Average target price 12,01 HKD
Spread / Average Target 53,8%
EPS Revisions
Managers and Directors
Cui Long Zhang Vice Chairman & Chief Executive Officer
Dong Chen Cai Chairman
Bo Wang Independent Non-Executive Director
Chuan Chen Independent Non-Executive Director
Chun Kwok Au Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CSPC PHARMACEUTICAL GROUP LTD.-7.79%11 856
JOHNSON & JOHNSON6.56%479 678
ELI LILLY AND COMPANY17.88%293 110
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202